Geron Corp GERN
Institutional shares held
491 Million
1.87M
calls
690K
puts
Total value of holdings
$1.71B
$6.51M
calls
$2.41M
puts
Market Cap
$1.26B
377,819,008
Shares Out.
Institutional ownership
129.89%
# of Institutions
274
We take great care to ensure that the data presented and summarized in this overview for GERON CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GERN
View all-
Black Rock Inc. New York, NY46.6MShares$155 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY44.1MShares$147 Million3.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.4MShares$108 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA32.3MShares$108 Million2.04% of portfolio
-
State Street Corp Boston, MA29MShares$96.7 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA28.9MShares$96.4 Million0.24% of portfolio
-
Vivo Capital, LLC Palo Alto, CA27.2MShares$90.9 Million18.09% of portfolio
-
Janus Henderson Group PLC London, X022.6MShares$75.4 Million0.05% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y922MShares$73.6 Million8.14% of portfolio
-
Holocene Advisors, LP New York, NY18.2MShares$60.7 Million0.36% of portfolio
Latest Institutional Activity in GERN
Top Purchases
Top Sells
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Transactions at GERN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Robert J. Spiegel |
SELL
Grant, award, or other acquisition
|
Direct |
1,767
-1.03%
|
-
|
|
Jul 08
2024
|
Andrew J Grethlein EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
674,348
-100.0%
|
$2,697,392
$4.56 P/Share
|
|
Jul 08
2024
|
Andrew J Grethlein EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
674,348
+50.0%
|
$674,348
$1.72 P/Share
|
|
Jun 28
2024
|
Robert J. Spiegel |
SELL
Grant, award, or other acquisition
|
Direct |
1,916
-1.12%
|
-
|
|
Jun 10
2024
|
Anil Kapur EVP, Corp Strategy & CCO |
SELL
Open market or private sale
|
Direct |
421,875
-100.0%
|
$1,687,500
$4.64 P/Share
|
|
Jun 10
2024
|
Anil Kapur EVP, Corp Strategy & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
421,875
+50.0%
|
$421,875
$1.06 P/Share
|
|
Jun 10
2024
|
Faye Feller EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
287,900
-100.0%
|
$1,151,600
$4.63 P/Share
|
|
Jun 10
2024
|
Faye Feller EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
287,900
+50.0%
|
$287,900
$1.14 P/Share
|
|
Jun 04
2024
|
John A Scarlett Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
600,000
-50.0%
|
$2,400,000
$4.0 P/Share
|
|
Jun 04
2024
|
John A Scarlett Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
600,000
+50.0%
|
$1,200,000
$2.54 P/Share
|
|
May 15
2024
|
V Bryan Lawlis |
SELL
Open market or private sale
|
Direct |
35,000
-100.0%
|
$105,000
$3.75 P/Share
|
|
May 15
2024
|
V Bryan Lawlis |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+50.0%
|
$35,000
$1.94 P/Share
|
|
Mar 29
2024
|
Robert J. Spiegel |
SELL
Grant, award, or other acquisition
|
Direct |
2,462
-1.46%
|
-
|
|
Dec 29
2023
|
Robert J. Spiegel |
BUY
Grant, award, or other acquisition
|
Direct |
3,406
+2.03%
|
-
|
|
Dec 29
2023
|
Gaurav Aggarwal |
BUY
Grant, award, or other acquisition
|
Direct |
1,970
+50.0%
|
-
|
|
Dec 29
2023
|
Susan Molineaux |
BUY
Grant, award, or other acquisition
|
Indirect |
6,220
+4.55%
|
-
|
|
Sep 29
2023
|
Robert J. Spiegel |
BUY
Grant, award, or other acquisition
|
Direct |
3,390
+2.07%
|
-
|
|
Sep 29
2023
|
Susan Molineaux |
BUY
Grant, award, or other acquisition
|
Indirect |
6,191
+4.74%
|
-
|
|
Aug 24
2023
|
Elizabeth G. O'Farrell |
BUY
Open market or private purchase
|
Indirect |
6,579
+20.06%
|
$13,158
$2.28 P/Share
|
|
Aug 24
2023
|
Elizabeth G. O'Farrell |
BUY
Open market or private purchase
|
Direct |
6,607
+47.15%
|
$13,214
$2.28 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.03M
Shares
From
8
Insiders
| Exercise of conversion of derivative security | 2.02M shares |
|---|---|
| Grant, award, or other acquisition | 11.6K shares |
Sell / Disposition
2.03M
Shares
From
6
Insiders
| Open market or private sale | 2.02M shares |
|---|---|
| Grant, award, or other acquisition | 6.15K shares |